Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jean-Luc Martinoli"'
Autor:
Theodore E. Spiro, Jean Luc Martinoli, Genevieve Contant, Elisabeth Perzborn, Gabriele Rohde, Meyer Michel Samama, Céline Guinet, Yves Gourmelin, Léna Le Flem
Publikováno v:
Thrombosis Journal
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation.
Autor:
Meyer Michel, Samama, Genevieve, Contant, Theodore E, Spiro, Elisabeth, Perzborn, Lena Le, Flem, Céline, Guinet, Yves, Gourmelin, Jean Luc, Martinoli, W, Wijns
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 18(2)
This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated in a field trial involving 2
Autor:
M.M. Samama, Gabriele Rohde, Theodore E. Spiro, Yves Gourmelin, Genevieve Contant, Jean-Luc Martinoli, Elisabeth Perzborn, Céline Guinet, L. Le Flem
Publikováno v:
European Journal of Hospital Pharmacy. 19:236.3-237
Background Rivaroxaban is an oral, direct Factor Xa inhibitor approved for clinical use for the prevention and treatment of thromboembolic disorders across several indications. Routine coagulation monitoring is not required, but a quantitative determ
Autor:
M.M. Samama, Genevieve Contant, Yves Gourmelin, Elisabeth Perzborn, Céline Guinet, Theodore E. Spiro, Jean-Luc Martinoli, L. Le Flem
Publikováno v:
European Journal of Hospital Pharmacy. 19:236.1-236
Background Rivaroxaban is widely used in clinical practice. Although routine coagulation monitoring is not required, quantitative determination of rivaroxaban might be valuable in certain clinical circumstances. Variation in response sensitivity of p
Autor:
Léna Le Flem, Jean Luc Martinoli, Yves Gourmelin, Meyer Michel Samama, Elisabeth Perzborn, Céline Guinet, Genevieve Contant, Theodore E. Spiro
Publikováno v:
Blood. 116:3330-3330
Abstract 3330 Background: Rivaroxaban is an oral, direct Factor Xa inhibitor in an advanced stage of clinical development for the prevention and treatment of thromboembolic disorders. It inhibits Factor Xa activity without requiring cofactors (such a
Autor:
Léna Le Flem, Céline Guinet, François Depasse, Jean-Luc Martinoli, Meyer Michel Samama, Elisabeth Perzborn
Publikováno v:
Blood. 112:3028-3028
Rivaroxaban is an oral, direct Factor Xa (FXa) inhibitor that has been recommended for approval by the Committee for Medicinal Products for Human Use for the prevention of venous thromboembolism after elective hip and knee replacement, and is in adva
Autor:
Jean-Luc Martinoli, Jean Amiral
Publikováno v:
Seminars in Thrombosis and Hemostasis. 9:194-205